Zydus Gets USFDA Tentative Nod for Mesalamine Suppositories | CORPORATE ETHOS

Zydus Gets USFDA Tentative Nod for Mesalamine Suppositories

By: | August 11, 2017
zydus

Aug 11: Drug maker Zydus Cadila on Friday received tentative approval from the USFDA to market its Mesalamine Suppositories for rectal use, 1000 mg.

According to the company, Mesalamine is used to treat an inflammatory bowel disease, such as ulcerative colitis. It will be produced at the group’s Topical plant at Ahmedabad.

Based in Ahmedabad, Zydus Cadila Group is a research-driven drug maker that discovers, develops, manufactures and markets a broad range of healthcare therapies.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.